Background/Aims: The study aim was to develop and validate models for long-term prediction of growth in prepubertal children with idiopathic growth hormone deficiency (GHD) or Turner syndrome (TS) for optimal, cost-effective growth hormone (GH) therapy. Methods: Height was predicted by sequential application of annual prediction algorithms for height velocity in cohorts of GHD (n = 664) and TS (n = 607) as documented within KIGS (Pfizer International Growth Database). As height prediction models also require an estimate of weight, new algorithms for weight increase during the first to fourth prepubertal years on GH were developed. Results: When height was predicted from the start of GH treatment, the predicted and observed mean (SD) gain over 4 years was 30.4 (3.4) cm and 30.1 (4.9) cm, respectively, in GHD patients, and 27.2 (2.2) cm and 26.6 (3.5) cm, respectively, in TS patients. For all 4 years, gains of weight SD scores (SDS) were accurately described as a function of weight SDS and observed gain in height SDS (R2 > 0.89). Conclusion: In GHD and TS patients treated with GH, an accurate prepubertal long-term prediction of height development in groups is possible. Based on this, an optimal individual height outcome could be simulated.

1.
Ranke MB, Lindberg A: Predicting growth in response to growth hormone treatment. Growth Horm IGF Res 2009;19:1–11.
2.
Albertsson-Wikland K, Kristrom B, Rosberg S, Svensson B, Nierop AF: Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. Am Pediatr Soc 2000;48:475–484.
3.
Schoenau E, Westermann F, Rauch F, Stabrey A, Wassmer G, Keller E, Brämswig J, Blum WF; German Lilly Growth Response Study Group: A new and accurate prediction model for growth response to growth hormone treatment in children with growth hormone deficiency. Eur J Endocrinol 2001;144:13–20.
4.
de Ridder MA, Stijnen T, Drop SL, Blum WF, Hokken-Koelega AC: Validation of a calibrated prediction model for response to growth hormone treatment in an independent cohort. Horm Res 2006;66:13–16.
5.
de Ridder MA, Stijnen T, Hokken-Koelega AC: Prediction of adult height in growth-hormone-treated children with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:925–931.
6.
Riis P: Thirty years of bioethics: the Helsinki Declaration 1964–2003. New Rev Bioeth 2003;1:15–25.
7.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab 1999;84:1174–1183.
8.
Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, Price DA; KIGS International Board & Kabi International Growth Study: Prediction of long-term response to recombinant human growth hormone in Turner Syndrome: development and validation of mathematical models. J Clin Endocrinol Metab 2000;85:4212–4218.
9.
Prader A, Largo RH, Molinari L, Issler C: Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr Acta Suppl 1989;52:1–125.
10.
Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA: Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17–24.
11.
Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P: An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977–1981). Acta Paediatr Scand 1991;80:756–762.
12.
Cole TJ: Some questions about how growth standards are used. Horm Res 1996;45(suppl):18–23.
13.
Weisberg S: Applied linear regression. Chichester, England, Wiley and Sons, 1985.
14.
Jung H, Land C, Nicolay C, De Schepper J, Blum WF, Schönau E: Growth response to an individualized versus fixed dose GH treatment in short children born small for gestational age: the OPTIMA study. Eur J Endocrinol 2009;160:149–156.
15.
Kriström B, Aronson AS, Dahlgren J, Gustafsson J, Halldin M, Ivarsson SA, Nilsson NO, Svensson J, Tuvemo T, Albertsson-Wikland K: Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature. J Clin Endocrinol Metab 2009;94:483–490.
16.
Kriström B, Dahlgren J, Niklasson A, Nierop AF, Albertsson-Wikland K: The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children. BMC Med Inform Decis Mak 2009;9:1.
17.
Blethen SL, Baptista J, Kuntze J, Foley T, LaFranchi S, Johanson A: Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. J Clin Endocrinol Metab 1997;82:418–420.
18.
Ranke MB, Lindberg A; KIGS International Board: Observed and predicted growth responses in prepubertal children with growth disorders: guidance of growth hormone treatment by empirical variables. J Clin Endocrinol Metab 2010;95:1229–1237.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.